VAL.L

ValiRx Plc
ValiRx PLC - Update on proposed sub-license of VAL401
20th November 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8786M
ValiRx PLC
20 November 2024
 

20 November 2024

 

ValiRx PLC

("ValiRx" or the "Company")

 

Update on proposed sub-license of VAL401

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that, further to the exclusive Option Agreement announced on 5 December 2023 between ValiSeek Limited ("ValiSeek") and Ambrose Healthcare Limited ("Ambrose Healthcare"), the Company has received notification from Ambrose Healthcare to exercise a six month extension to the option period granted to it under the original agreement (the "Extension").

Under the Extension, Ambrose Healthcare has a further 6-month period of exclusivity under which it may exercise the option to execute a global, exclusive license of Valiseek's VAL401 asset under pre-agreed terms.

All other terms remain unchanged with Ambrose Healthcare commiting to completing development and commercialisation of VAL401 at Ambrose's cost.

VAL401 is in development for Pancreatic ductal adenocarcinoma.

 

Mark Eccleston, CEO of ValiRx commented "This 6 month extension was available to Ambrose Healthcare under the terms of the initial agreement and has been exercised to give them further time to complete their funding process."

*** ENDS ***

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

For more information, please contact:

 

ValiRx plc

 

Dr Mark Eccleston, CEO

 

 

Tel: +44 (0) 115 784 0026

www.valirx.com

Mark.eccleston@valirx.com

 

 

V Formation (Public Relations)

 

Lucy Wharton - Senior PR Executive

Sue Carr - Director

 

+44 (0) 115 787 0206

www.vformation.biz

 

lucy@vformation.biz

sue@vformation.biz

Cairn Financial Advisers LLP (Nominated Adviser)

 

Liam Murray / Ludovico Lazzaretti

 

Tel: +44 (0) 20 7213 0880

Shard Capital Partners LLP (Sole Broker)

 

Damon Heath

 

Tel: +44 (0) 20 7186 9000

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. 

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUKVORSKUAAUA]]>
TwitterFacebookLinkedIn